| ABEONA THERAPEUTICS |
| USA |
| Gesundheit |
| US00289Y2063 / A3DMHM |
| PCJ (Frankfurt) / ABEO (NASDAQ) |
| FRA:PCJ, ETR:PCJ, PCJ:GR, NASDAQ:ABEO |
| - |
| https://www.abeonatherape.. |
|
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious, life-threatening rare diseases. Its flagship product, ZEVASKYN (prademagene zamikeracel), is the first and only autologous cell-b..
>Volltext.. |
| 208.65 Mio. EUR |
| 68.2 Mio. EUR |
| 5.03 Mio. EUR |
| -74.26 Mio. EUR |
| 61.55 Mio. EUR |
| 1.18 EUR |
| 21.59 Mio. EUR |
| 67.82 Mio. EUR |
| -65.99 Mio. EUR |
| 6.47 |
| - |
| - |
| - |
| - |
| - |
| ABEONA THERAPEUTICS, ABEONA THERAPEUTIC |
| 02.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|